1. Spinal and bulbar muscular atrophy
[
11 clinical trials,
14 drugs（DrugBank:
8 drugs),
10 target genes / 15 target pathways ]
Searched query = "Spinal and bulbar muscular atrophy", "Spinobulbar muscular atrophy", "Kennedy disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03555578 | November 2, 2017 | 20 August 2018 | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA) | Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA) | Spinal and Bulbar Muscular Atrophy | Drug: Leuprorelin Acetate | Takeda | Recruiting | N/A | N/A | All | 300 | Phase 1 | Japan | |
| 2 | JPRN-UMIN000026150 | 2017/04/25 | 2 April 2019 | Safety and efficacy of mexiletine hydrochroride in spinal and bulbar muscular atrophy (SBMA) :a multicenter, randomised, double-blind, placebo-controlled trial | Spinal and Bulbar Muscular Atrophy | Mexiletine Hydrochloride 300mg daily, for 4 weeks placebo for 4 weeks | Nagoya University Graduate School of Medicine | Not Recruiting | 20years-old | 80years-old | Male | 20 | Phase 2 | Japan | ||
| 3 | JPRN-UMIN000012503 | 2014/06/01 | 2 April 2019 | Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical study | Spinal and Bulbar Muscular Atrophy | Creatine monohydrate 10 g, daily for 8 weeks Creatine monohydrate 15 g, daily for 8 weeks placebo for 8 weeks | Department of Neurology, Nagoya University Graduate School of Medicine | Not Recruiting | 20years-old | 80years-old | Male | 45 | Not applicable | Japan | ||
| 4 | NCT02024932 | February 4, 2014 | 15 April 2019 | Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy | A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA) | Spinal and Bulbar Muscular Atrophy | Drug: BVS857;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | Male | 37 | Phase 2 | United States;Denmark;Germany;Italy | |
| 5 | JPRN-JMA-IIA00080 | 02/2012 | 22 July 2019 | Phase 2 Clinical Trial of Leuprorelin acetate in patients with SBMA (JASMITT-2) | Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal and Bulbar Muscular Atrophy (SBMA) | Spinal and Bulbar muscular atrophy | Intervention type:DRUG. Intervention1:TAP-144-SR(3M) , Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS. | JASMITT Clinical Trial Office | Jichi med college, Chiba univ., Univ of Tokyo, Tokyo med & dental univ. | Not Recruiting | >=30 YEARS | <70 YEARS | Male | 100 | Phase 2 | Japan |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2010-022558-18-IT | 11/10/2010 | 2 October 2012 | A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA). | A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA). | spinal and bulbar muscular atrophy (SBMA) MedDRA version: 15.0 Level: HLGT Classification code 10029317 Term: Neuromuscular disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 15.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 15.0 Level: LLT Classification code 10047868 Term: Weakness of limbs System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 15.0 Level: PT Classification code 10013969 Term: Dyspnoea at rest System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: MONORES*30CPR 20MCG Pharmaceutical Form: Capsule, hard INN or Proposed INN: Clenbuterol Concentration unit: µg microgram(s) Concentration number: 20- | AZIENDA OSPEDALIERA DI PADOVA | Authorised | Female: no Male: yes | Italy | |||||
| 7 | NCT00851461 | April 2008 | 1 June 2015 | Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy | Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients | Spinobulbar Muscular Atrophy;Kennedy's Disease | Drug: Goserelin;Procedure: Electrophysiologic study;Procedure: tissue biopsy | Ramathibodi Hospital | AstraZeneca | Not recruiting | 20 Years | N/A | Male | 10 | Phase 4 | Thailand |
| 8 | JPRN-JMA-IIA00009 | 13/09/2006 | 2 April 2019 | Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT) | Double-blind Placebo-controlled Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) | Spinal and Bulbar Muscular Atrophy (SBMA) | Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS. | JASMITT Clinical Trial Office | Hokkaido University, Tohoku University, Jichi Medical College, Chiba University, University of Tokyo, Tokyo Medical and Dental University, NHO Sagamitara hospital, Niigata University, Hamamatsu Medical college, Kobe University, Tottori University, Nagasaki University, Kumamoto University | Not Recruiting | >=30 YEARS | <70 YEARS | Male | 170 | Phase 3 | Japan |
| 9 | NCT00303446 | March 2006 | 19 October 2017 | Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) | Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) | Kennedy's Disease;Spinal and Bulbar Muscular Atrophy | Drug: Dutasteride;Drug: Placebo | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | Male | 57 | Phase 2 | United States | |
| 10 | JPRN-UMIN000000474 | 2003/09/01 | 2 April 2019 | Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) | Spinal and bulbar muscular atrophy (SBMA) | Leuprorelin acetate 3.75 mg subcutaneous injection every 4 weeks Placebo subcutaneous injection every 4 weeks | Department of Neurology, Nagoya University School of Medicine | Not Recruiting | 30years-old | 70years-old | Male | 40 | Phase 2 | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00004771 | October 1992 | 19 February 2015 | Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease | Spinal Muscular Atrophy;Amyotrophic Lateral Sclerosis;Spinobulbar Muscular Atrophy | Drug: leuprolide;Drug: testosterone | National Center for Research Resources (NCRR) | Ohio State University | Not recruiting | 18 Years | N/A | Male | 40 | Phase 2 |